Hope for kids with batten disease: new drug trial launches
NCT ID NCT04637282
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This study tests an experimental drug called PLX-200 in children aged 6 to 18 with mild-to-moderate CLN3 disease (a form of Batten disease). The goal is to see if the drug can slow down the disease and is safe. About 39 participants will receive either PLX-200 or a placebo, and researchers will track changes in motor skills, vision, language, and seizures over 60 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for JUVENILE NEURONAL CEROID LIPOFUSCINOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.